Rawat Mahika, Ng Chiao, Khan Emaad, Shah Rayyan A, Ashfaq Suha, Bahader Ghaith A, Shah Zahoor A
Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA.
Neural Regen Res. 2023 Sep;18(9):1881-1883. doi: 10.4103/1673-5374.367927.
Coronavirus disease 2019 (COVID-19) has affected a broad demographics, eliciting a more significant effect on specific groups such as males, African Americans, and Hispanic minorities. Treatment of COVID-19 often requires antiviral drugs or monoclonal antibodies. However, immunotherapies such as mesenchymal stem cells and mesenchymal stem cells-derived exosomal vesicles should be evaluated as treatment options for COVID-19. Mesenchymal stem cell therapy offers regenerative, anti-inflammatory, and immunomodulatory properties that can speed up the recovery from COVID-19. Mesenchymal stem cell therapy can also benefit COVID-19 patients who suffer from strokes, as COVID-19 increases the risk of strokes due to increased cytokines and clotting factors. Most stroke cases that occur in COVID-19 patients are ischemic strokes. Therefore, with the help of mesenchymal stem cell therapy and mesenchymal stem cells-derived exosomes, COVID-19-induced stroke patients might benefit from dual-ended treatment. The objective of this review was to discuss COVID-19 and stroke incidence and the available treatment options.
2019年冠状病毒病（COVID-19）已影响广泛的人群，对男性、非裔美国人以及西班牙裔少数群体等特定群体产生了更显著的影响。COVID-19的治疗通常需要抗病毒药物或单克隆抗体。然而，诸如间充质干细胞和间充质干细胞衍生的外泌体等免疫疗法应作为COVID-19的治疗选择进行评估。间充质干细胞疗法具有再生、抗炎和免疫调节特性，可加速COVID-19的康复。间充质干细胞疗法对患有中风的COVID-19患者也有益，因为由于细胞因子和凝血因子增加，COVID-19会增加中风风险。COVID-19患者中发生的大多数中风病例为缺血性中风。因此，在间充质干细胞疗法和间充质干细胞衍生的外泌体的帮助下，COVID-19诱发的中风患者可能会从双管齐下的治疗中受益。本综述的目的是讨论COVID-19与中风发病率以及现有的治疗选择。
